Statement: Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months.
Primary_evidence: Outcome Measurement:    Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)   Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.   Time frame: Baseline, 24 months Results 1:    Arm/Group Title: Letrozole   Arm/Group Description: 2.5 mg once daily (q.d.)orally for 5 years   Overall Number of Participants Analyzed: 63   Median (Full Range)   Unit of Measure: Percent Change  -4.63        (-14.21 to 4.32) Results 2:    Arm/Group Title: Tam-Let   Arm/Group Description: 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.   Overall Number of Participants Analyzed: 68   Median (Full Range)   Unit of Measure: Percent Change  0.37        (-6.98 to 15.21)